ResearcherEmory UniversityActive in the last 2 years
Cameron J. Herting
Matched on ORCID iD 0000-0002-4937-8392; OpenAlex author ID A5019313069. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers
Papers 5
- A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling. Co-author DOI 10.1016/j.canlet.2025.218233↗
- High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-25-1697↗
- Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Co-author DOI 10.1016/j.xcrm.2024.101881↗
- Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy. Co-author DOI 10.1136/jitc-2023-008086↗
- The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions. Co-author DOI 10.1007/s10555-021-09988-w↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Gregory B. Lesinski · 5 shared papers, 2021–2026 · strength 1.08
- Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
- Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
- Paper The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions. DOI 10.1007/s10555-021-09988-w↗
- Chrystal M Paulos · 3 shared papers, 2024–2026 · strength 0.67
- Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
- Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
- Paper Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy. DOI 10.1136/jitc-2023-008086↗
- Natalie K. Horvat · 3 shared papers, 2024–2026 · strength 0.67
- Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
- Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
- Paper Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy. DOI 10.1136/jitc-2023-008086↗
- Olatunji Boladale Alese · 3 shared papers, 2025–2026 · strength 0.66
- Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
- Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
- Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
- Bassel F. El‐Rayes · 3 shared papers, 2025–2026 · strength 0.66
- Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
- Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
- Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
- Emily R. Greene · 2 shared papers, 2026 · strength 0.47
- Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
- Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
- Maria Diab · 2 shared papers, 2026 · strength 0.47
- Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
- Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
- Olumide B. Gbolahan · 1 shared paper, 2026 · strength 0.24
- Juan Manuel Sarmiento · 1 shared paper, 2026 · strength 0.23
- Alyssa M. Krasinskas · 1 shared paper, 2026 · strength 0.23
- Mihir Maheshkumar Shah · 1 shared paper, 2026 · strength 0.23
- Shishir Kumar Maithel · 1 shared paper, 2026 · strength 0.23
- Richard A. Moffitt · 1 shared paper, 2024 · strength 0.20
- Upender Manne Manne · 1 shared paper, 2025 · strength 0.19
- Yuvasri Golivi · 1 shared paper, 2025 · strength 0.19
- Julienne L. Carstens · 1 shared paper, 2025 · strength 0.19
- Ashiq Masood · 1 shared paper, 2025 · strength 0.19
- Sujith Sarvesh · 1 shared paper, 2025 · strength 0.19
- Dhana Sekhar Reddy Bandi · 1 shared paper, 2025 · strength 0.19
- Manoj Bhasin · 1 shared paper, 2025 · strength 0.19
- Karina Jin Yoon · 1 shared paper, 2025 · strength 0.19
- Ganji Purnachandra Nagaraju · 1 shared paper, 2025 · strength 0.19
- Jeremy B. Foote · 1 shared paper, 2025 · strength 0.19
- Mehmet Akce · 1 shared paper, 2025 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.